{"filings":[{"id":106903,"accession_number":"0001193125-26-133247","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["3.01","8.01"],"status":"ready","headline":"Iterum Therapeutics to be delisted from Nasdaq on April 1 after winding-up petition","event_type":"other_material","confidence":"high","bullets":["Nasdaq will suspend ITRM shares at open on April 1, 2026; Form 25-NSE to follow.","Company withdrew its appeal of the prior delisting determination after filing winding-up petition on March 27, 2026.","Joint provisional liquidators Damien Murran and Jennifer McMahon (Teneo) appointed; company in provisional liquidation.","Iterum will not file Form 10-K for FY 2025 or any future SEC reports due to limited cash resources and winding-up process."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.95,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106902,"accession_number":"0001193125-26-127785","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["1.03","2.04","5.02","7.01","9.01"],"status":"ready","headline":"Iterum Therapeutics files for winding up in Ireland; appoints provisional liquidators; CEO/CFO resign","event_type":"other_material","confidence":"high","bullets":["Filed winding-up petition in Irish High Court; joint provisional liquidators appointed (Damien Murran, Jennifer McMahon of Teneo).","CEO Corey Fishman and CFO Judith Matthews resigned effective immediately after petition filing.","Filing triggered default under Royalty-Linked Notes; default interest rate set at prime plus 3%.","Company cites limited cash, inability to raise capital, failed strategic alternatives, and modest ORLYNVAH sales as reasons.","Nasdaq trading suspension expected March 27; shareholders likely to experience complete loss."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":1.0,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106901,"accession_number":"0001193125-26-088494","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Iterum Therapeutics requests Nasdaq hearing to appeal delisting; warns of possible wind-down","event_type":"other_material","confidence":"high","bullets":["On March 3, 2026, Iterum requested a hearing before Nasdaq Hearings Panel to appeal delisting for failure to maintain $1.00 bid price.","Hearing request automatically stays suspension scheduled for March 5, 2026, pending the hearing and any extension.","Company also fails to meet $35M minimum market value of listed securities requirement; compliance deadline June 9, 2026.","Evaluating strategic alternatives including possible wind-down, bankruptcy, licensing or sale of assets.","Company states limited ability to raise capital; shareholders very unlikely to receive distribution in a wind-down."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106900,"accession_number":"0001193125-26-085646","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Iterum Therapeutics receives Nasdaq delisting notice; shares to suspend Mar 5, 2026","event_type":"other_material","confidence":"high","bullets":["Received delisting determination letter on Feb 24, 2026 for failing minimum bid price of $1.00 per share.","Trading suspension on Nasdaq effective March 5, 2026 unless hearing requested before Nasdaq Hearings Panel.","Company evaluating appeal and strategic alternatives including possible wind-down or bankruptcy.","Also noncompliant with $35M minimum market value of listed securities and other listing standards.","Warns shareholders are unlikely to receive any meaningful distribution in a potential dissolution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.95,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106899,"accession_number":"0001193125-26-057393","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2026-02-18T23:59:59+00:00","items":["5.07","8.01"],"status":"ready","headline":"Iterum shareholders reject all four EGM proposals; company warns of possible wind-down","event_type":"other_material","confidence":"high","bullets":["Shareholders voted against increasing authorized share capital (12.8M for vs 17.9M against).","Reverse share split proposal also defeated: 13.9M for vs 16.7M against.","Directors' allotment authority and pre-emption opt-out similarly rejected.","Company says vote results restrict ability to raise capital, harming operations and going concern.","Management warns of possible wind-down, bankruptcy, or liquidation; shareholders unlikely to receive distribution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":1.0,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123222,"accession_number":"0001193125-25-317728","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Iterum Therapeutics receives Nasdaq delisting notice for MVLS below $35M","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Iterum on Dec 11, 2025 that MVLS <$35M for 30 consecutive business days; given 180 days until June 9, 2026 to regain compliance.","Company also remains out of compliance with $1.00 minimum bid price rule since August 2025, with compliance period ending Feb 23, 2026.","Failure to cure either deficiency could lead to delisting; company may appeal but no assurance of success.","Notice has no immediate effect on listing; common stock continues trading on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123221,"accession_number":"0001193125-25-281531","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Iterum Therapeutics Q3 2025: ORLYNVAH launch nets $0.4M revenue; cash runway extended to Q2 2026","event_type":"earnings","confidence":"high","bullets":["Net product revenue of $0.4M from ORLYNVAH launch in August 2025; 2026 sales guidance $5M-$15M.","Cash and equivalents $11.0M as of Sep 30, 2025; additional $2.6M raised Oct-Nov 2025 extends runway into Q2 2026.","GAAP net loss $9.0M ($0.81 diluted EPS); non-GAAP net loss $7.3M vs. $6.1M and $4.8M in Q3 2024.","SG&A expenses rose to $6.5M from $1.8M YoY due to commercialization; R&D fell to $1.3M.","Granted patents in China and Mexico covering sulopenem combinations; IDWeek posters presented."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":390000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123220,"accession_number":"0001193125-25-241556","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2025-10-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Iterum files $20M ATM offering; ORLYNVAH launched Aug 2025 with modest sales expected","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement for ATM offering of up to $20M aggregate gross proceeds (max ~21.8M ordinary shares).","Previously raised approximately $36.2M under same Sales Agreement with H.C. Wainwright.","ORLYNVAH commercially launched in U.S. in August 2025; company expects modest sales in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139900,"accession_number":"0000950170-25-113986","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2025-09-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Iterum shareholders reject say-on-pay, share increase, and equity plan at AGM","event_type":"other_material","confidence":"high","bullets":["David Kelly elected Class I director with 10.8M for, 2.8M against, 0.7M abstain, 8.2M broker non-votes.","Say-on-pay failed: 5.4M for (38.5%), 8.4M against, 0.5M abstain.","Share capital increase to $2.6M (add 80M shares) rejected: 6.5M for, 15.8M against.","Equity incentive plan amendment to add 4M shares rejected: 2.5M for, 11.3M against.","Allotment authority and pre-emption opt-out also failed by wide margins."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139899,"accession_number":"0000950170-25-111974","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2025-08-28T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Iterum Therapeutics receives Nasdaq delisting notice for bid price below $1.00","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notice for non-compliance with minimum bid price rule; shares traded below $1.00 for 30 consecutive business days.","180-day cure period expires February 23, 2026; must close at $1.00 for 10 consecutive business days to regain compliance.","May qualify for an additional 180-day period if it meets other listing standards and intends to cure via reverse split.","Failure to cure could lead to delisting; company will monitor options but no assurance of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139898,"accession_number":"0000950170-25-110370","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2025-08-20T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Iterum launches ORLYNVAH, first oral penem antibiotic in U.S., for uUTI","event_type":"other_material","confidence":"high","bullets":["FDA approved ORLYNVAH in Oct 2024; commercial launch announced Aug 20, 2025.","First oral penem antibiotic in U.S.; first new branded uUTI product in >25 years.","57% of initial uUTIs resistant to at least one antibiotic class per 2024 study.","Copay savings program allows eligible patients to get ORLYNVAH for as low as $25.","CEO cites urgent need for new oral therapies amid rising antibiotic resistance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139897,"accession_number":"0000950170-25-102394","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Iterum reports Q2 net loss $6.5M; ORLYNVAH launch on track for August 2025","event_type":"earnings","confidence":"high","bullets":["Net loss $6.5M (non-GAAP $5.1M) vs $5.0M prior year; cash $13.0M at June 30, 2025.","ORLYNVAH™ launch expected by end of August 2025 for uUTIs; first oral penem approved in U.S.","Entered commercialization agreement with EVERSANA; hired Christine Coyne as CCO.","Pfizer extended $20M milestone payment deferral to October 2029.","Canadian patent issued covering sulopenem/probenecid combination, expiring 2039."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139896,"accession_number":"0000950170-25-101971","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Iterum Therapeutics enters 5-year manufacturing supply agreement with ACS Dobfar for ORLYNVAH","event_type":"other_material","confidence":"high","bullets":["Agreement covers commercial manufacture and supply of ORLYNVAH bilayer tablets and sulopenem etzadroxil bulk drug substance.","Initial term of 5 years with a 2-year automatic renewal; pricing based on per kg or per bottle.","Iterum Ireland provides rolling forecasts, with portion binding as firm orders; ACS to use commercially reasonable efforts for above-forecast orders.","Agreement includes customary IP protection, confidentiality, insurance, indemnification, and cGMP compliance obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139895,"accession_number":"0000950170-25-096984","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2025-07-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Iterum sets 2025 AGM for Sept 10; shareholder proposals due July 28","event_type":"other","confidence":"high","bullets":["Annual General Meeting scheduled for September 10, 2025.","Record date for voting eligibility is July 15, 2025.","Deadline for shareholder proposals under Rule 14a-8 is July 28, 2025.","Deadline for director nominations and other proposals is July 28, 2025.","Meeting is more than 30 days later than prior year's AGM, triggering new deadlines."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157495,"accession_number":"0000950170-25-084650","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Iterum Therapeutics enters commercialization agreement with EVERSANA for ORLYNVAH in US","event_type":"other_material","confidence":"high","bullets":["Eversana will be exclusive provider of sales, marketing, logistics, regulatory, and medical affairs services for ORLYNVAH.","ITUS retains legal, regulatory, manufacturing, and books sales; pays fees and expenses per statements of work.","Term is 5 years from commercial launch; either party can terminate for material breach, insolvency, or certain law changes.","ITUS or change-of-control counterparty may terminate upon paying specified fees; Eversana can terminate if ORLYNVAH is withdrawn.","Agreement includes customary confidentiality, indemnification, and liability limitations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157494,"accession_number":"0000950170-25-073950","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"Iterum extends $20M Pfizer milestone payment to Oct 2029; interest rises to 10%","event_type":"debt","confidence":"high","bullets":["$20M regulatory milestone due Oct 2026 extended to Oct 2029 via amended promissory note.","Interest rate increases from 8% to 10%, compounded daily, starting Oct 26, 2026.","ITIL pays Pfizer a transaction fee plus legal expenses; no senior debt or liens without Pfizer consent.","CEO says extension allows capital to be invested in ORLYNVAH launch and geographic expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157493,"accession_number":"0000950170-25-069794","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Iterum Therapeutics Q1 net loss $4.9M; preparing for ORLYNVAH launch by Q4 2025","event_type":"other_material","confidence":"high","bullets":["Net loss of $4.9M in Q1 2025 vs $7.1M in Q1 2024; non-GAAP net loss $3.3M vs $5.8M.","Cash and equivalents $12.7M at March 31, 2025; extended runway into 2026 via $5M registered direct offering and ~$1M ATM proceeds.","Preparing for potential launch of ORLYNVAH (oral sulopenem) for uUTIs by Q4 2025; FDA approved October 2024.","Repaid $6.5M 6.500% exchangeable senior subordinated notes due 2025 in January 2025.","R&D expense fell to $0.6M (from $4.0M) due to REASSURE trial wind-down; G&A rose to $2.8M on pre-commercialization costs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157492,"accession_number":"0001193125-25-105148","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Iterum Therapeutics announces $5M registered direct offering of ordinary shares and pre-funded warrants","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $5.0M from sale of 5,555,556 shares/warrants at $0.90 each.","Net proceeds ~$4.2M after fees; H.C. Wainwright acting as placement agent.","Funding to support pre-commercialization of ORLYNVAH and strategic process, cash runway into 2026.","Offering expected to close April 30, 2025, subject to customary conditions.","Pre-funded warrants exercisable at $0.01 per share with 9.99% beneficial ownership cap."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175871,"accession_number":"0000950170-25-035943","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Iterum Therapeutics appoints Joseph Whalen to board; David Kelly named Chairman","event_type":"leadership","confidence":"high","bullets":["Joseph J. Whalen appointed as Class III director effective March 10, 2025; term expires at 2027 AGM.","Whalen joins Audit and Compensation Committees; receives annual cash retainers of $35,000 (board), $7,500 (audit), $6,000 (compensation).","David Kelly appointed Chairman of the Board effective March 10, 2025, after Ronald Hunt resigned on February 14, 2025.","Whalen's appointment restores Audit Committee to three independent members, regaining Nasdaq Listing Rule 5605(c)(2)(A) compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}